Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| ARRY | Array BioPharma Inc. | -0.24% | 46.26 | 8.1% | $690.49m | |
| AMGN | Amgen Inc. | -0.23% | 177.06 | 1.3% | $495.97m | |
| CELG | Celgene Corporation | -0.72% | 90.87 | 1.3% | $431.27m | |
| GILD | Gilead Sciences, Inc. | -0.03% | 66.92 | 0.9% | $401.89m | |
| BIIB | Biogen Inc. | -0.91% | 229.44 | 1.3% | $372.09m | |
| ILMN | Illumina, Inc. | 0.20% | 302.90 | 3.5% | $354.87m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 0.35% | 299.42 | 2.6% | $268.31m | |
| ALXN | Alexion Pharmaceuticals, Inc. | 0.48% | 123.41 | 2.0% | $197.95m | |
| SRPT | Sarepta Therapeutics, Inc. | 0.49% | 154.00 | 14.7% | $197.25m | |
| VRTX | Vertex Pharmaceuticals Incorporated | 0.56% | 177.14 | 1.9% | $181.72m | |
| A | Agilent Technologies, Inc. | -0.52% | 69.59 | 1.6% | $140.09m | |
| EXAS | Exact Sciences Corporation | 1.21% | 116.34 | 24.1% | $137.96m | |
| INCY | Incyte Corporation | 0.44% | 80.23 | 2.5% | $110.35m | |
| BLUE | Bluebird Bio, Inc. | 4.33% | 139.45 | 14.3% | $97.87m | |
| BMRN | BioMarin Pharmaceutical Inc. | 0.12% | 82.47 | 4.3% | $84.42m |
Company Profile
BioTime, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Alameda, CA.